Safety and tolerability of sequential pegylated IFN-α2a and tenofovir for hepatitis B infection in HIV+ individuals

HIV Clinical Trials

Volumn 8, Issue 3, 2007, Pages 173-181

  Johnson, Raymond M ^a,d   Ristig, M B ^b   Overton, E T ^b   Lisker Melman, M ^b   Cummings, O W ^a   Aberg, J A ^c  

^a INDIANA UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d Division of Infectious Diseases   (United States)

Author keywords

HBV; HIV; Phase 1 clinical trial; Resistance; Suppression

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; EMTRICITABINE; ERYTHROPOIETIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; LAMIVUDINE; NUCLEOSIDE; NUCLEOTIDE; PEGINTERFERON ALPHA2A; TENOFOVIR;

ADULT; ANEMIA; ANOREXIA; ARTICLE; BACTERIAL ENDOCARDITIS; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; FATIGUE; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; MALE; MONOTHERAPY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PHASE 1 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE; TASTE DISORDER; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; XEROSTOMIA;

ADENINE; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS;

EID: 34547207673     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0803-173     Document Type: Article

References (43)

1. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296(7): 827-843.
2. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005;19(3):221-240.
3. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis. 2006;43(7):904-910.
4. Shire NJ, Sherman KE. Management of HBV/HIV-coinfected patients. Semin Liver Dis. 2005;25(suppl 1):48-57.
5. Thio CL, Sulkowski MS, Thomas DL. Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. Clin Infect Dis. 2005;41(7):1035-1040.
6. Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol. 2006;44S1:S90-S94.
7. Tran TT, Martin P. Hepatitis B: epidemiology and natural history. Clin Liver Dis. 2004;8(2):255-266.
8. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921-1926.
9. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002;162(18):2125-2132.
10. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med. 2003;4(3):241-249.
11. Law WR Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004;18(8):1169-1177.
12. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188(4):571-577.
13. Mocroft A, Soriano V, Rockstroh J, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS. 2005;19(18):2117-2125.
14. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42(6):799-805.
15. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18(15):2039-2045.
16. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29(4):1306-1310.
17. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 1997;11(5):597-606.
18. Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology. 2002;123(6):1812-1822.
19. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65-73.
20. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology. 2006;43(3):548-555.
21. Nunez M, Ramos B, Diaz-Pollan B, et al. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses. 2006;22(9):842-848.
22. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology. 2006;44(5):1110-1116.
23. Schmutz G, Nelson M, Lutz T, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS. 2006;20(15):1951-1954.
24. Jain MK, Comanor L, White C, et al. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat. 2007;14(3):176-182.
25. Lacombe K, Gozlan J, Boelle PY, et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS. 2005;19(9):907-915.
26. Stephan C, Berger A, Carlebach A, et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother. 2005;56(6):1087-1093.
27. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS. 2003;17(1):F7-10.
28. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005;10(6):727-734.
29. Wong DK, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology. 1995;108(1):165-171.
30. McDonald JA, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology. 1987;7(4):719-723.
31. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682-2695.
32. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451-459.
33. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-450.
34. Barrios A, Rendon A, Negredo E, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS. 2005;19(6):569-575.
35. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839-2848.
36. Alazemi S, Campos MA. Interferon-induced sarcoidosis. Int J Clin Pract. 2006;60(2):201-211.
37. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32(4 pt 1):803-806.
38. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003;37(4):748-755.
39. Park SG, Kim Y, Park E, Ryu HM, Jung G. Fidelity of hepatitis B virus polymerase. Eur J Biochem. 2003;270(14):2929-2936.
40. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808-816.
41. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001-1010.
42. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005;128(7):1890-1897.
43. Anderson AL, Banks KE, Pontoglio M, Yaniv M, McLachlan A. Alpha/beta interferon differentially modulates the clearance of cytoplasmic encapsidated replication intermediates and nuclear covalently closed circular hepatitis B virus (HBV) DNA from the livers of hepatocyte nuclear factor 1 alpha-null HBV transgenic mice. J Virol. 2005;79(17):11045-11052.